CY1124115T1 - Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες - Google Patents
Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχεςInfo
- Publication number
- CY1124115T1 CY1124115T1 CY20211100204T CY211100204T CY1124115T1 CY 1124115 T1 CY1124115 T1 CY 1124115T1 CY 20211100204 T CY20211100204 T CY 20211100204T CY 211100204 T CY211100204 T CY 211100204T CY 1124115 T1 CY1124115 T1 CY 1124115T1
- Authority
- CY
- Cyprus
- Prior art keywords
- glyceryl
- disorders
- neurodegenerate
- tribenzoic
- containing composition
- Prior art date
Links
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical class OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- ITRIWXSLDIKBHK-UHFFFAOYSA-N (3-benzoyloxy-2-hydroxypropyl) benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC(O)COC(=O)C1=CC=CC=C1 ITRIWXSLDIKBHK-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- HIZCTWCPHWUPFU-UHFFFAOYSA-N Glycerol tribenzoate Chemical compound C=1C=CC=CC=1C(=O)OCC(OC(=O)C=1C=CC=CC=1)COC(=O)C1=CC=CC=C1 HIZCTWCPHWUPFU-UHFFFAOYSA-N 0.000 abstract 1
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000030954 urea cycle disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461928622P | 2014-01-17 | 2014-01-17 | |
| PCT/US2015/011798 WO2015109215A1 (en) | 2014-01-17 | 2015-01-16 | The use of a benzoate containing composition in urea cycle disorders and neurodegenerativre disordrs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124115T1 true CY1124115T1 (el) | 2022-05-27 |
Family
ID=53543490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100204T CY1124115T1 (el) | 2014-01-17 | 2021-03-09 | Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9968582B2 (enExample) |
| EP (1) | EP3094616B1 (enExample) |
| JP (2) | JP6836905B2 (enExample) |
| CA (1) | CA2936548C (enExample) |
| CY (1) | CY1124115T1 (enExample) |
| DK (1) | DK3094616T3 (enExample) |
| ES (1) | ES2853974T3 (enExample) |
| HR (1) | HRP20210361T1 (enExample) |
| HU (1) | HUE053671T2 (enExample) |
| LT (1) | LT3094616T (enExample) |
| PL (1) | PL3094616T3 (enExample) |
| PT (1) | PT3094616T (enExample) |
| RS (1) | RS61611B1 (enExample) |
| SI (1) | SI3094616T1 (enExample) |
| SM (1) | SMT202100074T1 (enExample) |
| WO (1) | WO2015109215A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3691630A4 (en) * | 2017-10-06 | 2021-10-27 | Rush University Medical Center | USE OF A COMPOSITION CONTAINING BENZOATE TO TREAT GLYCINE ENCEPHALOPATHY |
| AU2018371628B2 (en) | 2017-11-22 | 2021-08-12 | Excelsior Pharmatech Labs | Benzoic acid or a salt and derivative thereof for use in preventing or treating depression |
| EA202192199A1 (ru) * | 2019-02-25 | 2021-12-17 | Раш Юниверсити Медикал Сентер | Композиции, содержащие коричную кислоту, и способы их применения |
| KR20220066253A (ko) * | 2019-07-16 | 2022-05-24 | 러쉬 유니버시티 메디컬 센터 | 신경퇴행성 장애를 치료하기 위한 벤조에이트 함유 조성물의 용도 |
| WO2022093922A1 (en) | 2020-10-28 | 2022-05-05 | Rush University Medical Center | Use of a cinnamein composition for the treatment of glycine encephalopathy and urea cycle disorders |
| EP4262781A4 (en) * | 2020-12-16 | 2025-02-12 | Rush University Medical Center | Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders |
| US20250057793A1 (en) * | 2021-12-16 | 2025-02-20 | The United States Government As Represented By The Department Of Veterans Affairs | Benzoic acid salts for treatment of nervous system injuries and disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US20080171792A1 (en) * | 2006-12-28 | 2008-07-17 | Jobdevairakkam Christopher New | Use of highly concentrated formulations of 4-phenylbutyrate for treatment of certain disorders |
-
2015
- 2015-01-16 HU HUE15737329A patent/HUE053671T2/hu unknown
- 2015-01-16 PT PT157373291T patent/PT3094616T/pt unknown
- 2015-01-16 LT LTEP15737329.1T patent/LT3094616T/lt unknown
- 2015-01-16 PL PL15737329T patent/PL3094616T3/pl unknown
- 2015-01-16 ES ES15737329T patent/ES2853974T3/es active Active
- 2015-01-16 SI SI201531511T patent/SI3094616T1/sl unknown
- 2015-01-16 US US15/110,702 patent/US9968582B2/en active Active
- 2015-01-16 HR HRP20210361TT patent/HRP20210361T1/hr unknown
- 2015-01-16 JP JP2016565117A patent/JP6836905B2/ja active Active
- 2015-01-16 CA CA2936548A patent/CA2936548C/en active Active
- 2015-01-16 SM SM20210074T patent/SMT202100074T1/it unknown
- 2015-01-16 WO PCT/US2015/011798 patent/WO2015109215A1/en not_active Ceased
- 2015-01-16 EP EP15737329.1A patent/EP3094616B1/en active Active
- 2015-01-16 RS RS20210230A patent/RS61611B1/sr unknown
- 2015-01-16 DK DK15737329.1T patent/DK3094616T3/da active
-
2019
- 2019-10-18 JP JP2019191224A patent/JP2020037558A/ja active Pending
-
2021
- 2021-03-09 CY CY20211100204T patent/CY1124115T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3094616T3 (da) | 2021-02-15 |
| ES2853974T3 (es) | 2021-09-20 |
| CA2936548A1 (en) | 2015-07-23 |
| SI3094616T1 (sl) | 2021-07-30 |
| CA2936548C (en) | 2022-08-30 |
| JP6836905B2 (ja) | 2021-03-03 |
| LT3094616T (lt) | 2021-04-12 |
| PL3094616T3 (pl) | 2021-05-31 |
| RS61611B1 (sr) | 2021-04-29 |
| JP2017505811A (ja) | 2017-02-23 |
| SMT202100074T1 (it) | 2021-05-07 |
| US9968582B2 (en) | 2018-05-15 |
| EP3094616B1 (en) | 2020-12-23 |
| WO2015109215A1 (en) | 2015-07-23 |
| HUE053671T2 (hu) | 2021-07-28 |
| JP2020037558A (ja) | 2020-03-12 |
| US20160331714A1 (en) | 2016-11-17 |
| EP3094616A1 (en) | 2016-11-23 |
| EP3094616A4 (en) | 2017-08-23 |
| HRP20210361T1 (hr) | 2021-04-16 |
| PT3094616T (pt) | 2021-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120529T1 (el) | Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων | |
| SA518391624B1 (ar) | Ror- منظمات جاما | |
| CY1121826T1 (el) | Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson | |
| ZA202001057B (en) | Inhibiting ubiquitin specific peptidase 30 | |
| EA201690107A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| PE20150092A1 (es) | Composiciones farmaceuticas que contienen fumarato de dimetilo | |
| JP2016515522A5 (enExample) | ||
| EA202090683A2 (ru) | Способы и композиции для лечения рака | |
| BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| MX2019003805A (es) | Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías. | |
| TR201905218T4 (tr) | Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler. | |
| EA201690191A1 (ru) | Фармацевтическая композиция для замедленного высвобождения ланреотида | |
| MX2015003732A (es) | Tratamiento de enfermedad de alzheimer leve y moderada. | |
| UA113975C2 (xx) | Застосування фармацевтичної композиції або добавки, яка містить фосфатидилсерин і куркумін (варіанти) | |
| MX2016008968A (es) | Compuestos organicos. | |
| CL2015001881A1 (es) | Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición. | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| EA202090666A1 (ru) | Применение содержащей бензоат композиции для лечения глициновой энцефалопатии | |
| SI3413870T1 (sl) | Igmezin za uporabo pri zdravljenju alzheimerjeve bolezni | |
| DOP2016000325A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas | |
| BR112017020180A2 (pt) | derivados de aminohidrotiazina fundida em tetrahidrofurano que são úteis no tratamento da doença de alzheimer | |
| MX366118B (es) | Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio. | |
| EA201790117A1 (ru) | Фармацевтическая композиция, содержащая 13 глицеридов, и ее препараты и их применение | |
| MX375329B (es) | 2,2,2-trifluoroetil-tiadiazinas. |